Telix Recognised by the Australian Financial Review as Australia’s Highest Achieving Company for International Growth
Telix has today been recognised as Australia’s highest achieving company for international growth in the Australian Financial Review’s Fast Global list.
Fast Global celebrates Australian companies that are delivering real commercial growth in international markets, calculated on growth in revenue generated outside of Australia over the past three years.
to officially open Telix Manufacturing Solutions, the Company’s radiopharmaceutical production facility located in Brussels South (Seneffe), in the Wallonia region of Belgium.
Located in the heart of Belgium’s ‘Radiopharma Valley’, the 2,800 square metre facility is one of Europe’s largest radiopharmaceutical production facilities. It will serve as the Company’s primary manufacturing site for radioisotopes and commercial and clinical products for patients in the Europe Middle East and Africa (EMEA) region and beyond.
Radiopharmaceuticals use targeting agents (small molecules or antibodies) to deliver targeted radiation to cancer cells, regardless of where the cancer is in the body. These agents can be used for imaging (diagnosis) or therapy. Often referred to as “theranostics”, this approach has the potential to better inform treatment decisions and deliver personalised therapy for patients.
The presentation will take place on Wednesday June 7 from 12.30pm – 12.55pm EDT (2.30am – 2.55am AEST, June 8).
A live webcast of the presentation will be available at the following link: https://wsw.com/webcast/jeff281/tlx/1727440
The webcast will be accessible on demand on the Telix website following the event.
Institutional investors, analysts and company guests are cordially invited to attend the session, which will feature an overview of the Company's growth strategy and product pipeline for the detection and treatment of urological cancers.
